Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience

Introduction: The hallmark of chronic myeloid leukemia (CML) is the development of the fusion gene, BCR-ABL which has unopposed tyrosine kinase activity. The first tyrosine kinase inhibitor (TKI) imatinib is claimed to have superior efficacy and side effect profile as compared to traditional treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Saleem, Umera, Hafeez, Talha, Raza, Syed Ali, Tahir, Muhammad, Khalid, Fatima, Islam, Muhammad Khurrum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249755/
https://www.ncbi.nlm.nih.gov/pubmed/32467801
http://dx.doi.org/10.7759/cureus.7826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249755/
https://www.ncbi.nlm.nih.gov/pubmed/32467801
http://dx.doi.org/10.7759/cureus.7826

Ejemplares similares